Abernethy Amy P, Raman Gowri, Balk Ethan M, Hammond Julia M, Orlando Lori A, Wheeler Jane L, Lau Joseph, McCrory Douglas C
Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, North Carolina, USA.
Ann Intern Med. 2009 Mar 3;150(5):336-43. doi: 10.7326/0003-4819-150-5-200903030-00107. Epub 2009 Feb 16.
The Centers for Medicare & Medicaid Services limit coverage of cancer drugs for off-label indications to indications listed in specified compendia.
To assess whether compendia provide comprehensive, research-based, and timely information for off-label prescribing in oncology.
6 drug compendia, English-language literature searches of MEDLINE and the Cochrane Central Register of Controlled Trials from 2006 and 2008, and American Society of Clinical Oncology annual meeting abstracts from 2004 to 2007. Data Assessment: The compendia's stated methods, literature related to off-label indications of 14 cancer drugs in 2006, updated literature related to 1 off-label indication between 2006 and 2008, and completeness of compendia content and citations were assessed.
The compendia's stated methods varied greatly from their actual practices. Compendia cited little of the available evidence, often neither the most recent nor that of highest methodological quality. Compendia differed in evidence cited, terminology, detail, presentation, and referencing. For the 14 off-label indications studied, the compendia differed in the indications included and whether and how they recommended particular agents for particular types of cancer. Update schedules varied, and documentation practices made it difficult to determine whether and when compendia content was updated. For 1 indication, compendia citations did not increase between 2006 and 2008 despite newly published articles.
The 2006 analysis was limited to 14 off-label indications; the 2008 update examined 1 indication. Only off-label indications for cancer drugs were included, and results cannot be generalized to noncancer drugs or indications.
Oncologists rely on compendia for up-to-date access to evidence and reimbursement information for off-label indications. Current compendia lack transparency, cite little current evidence, and lack systematic methods to review or update evidence.
医疗保险和医疗补助服务中心将癌症药物用于非标签适应症的保险范围限制在特定药典中列出的适应症。
评估药典是否为肿瘤学中的非标签处方提供全面、基于研究且及时的信息。
6部药物药典、2006年和2008年对MEDLINE和Cochrane对照试验中央注册库进行的英文文献检索,以及2004年至2007年美国临床肿瘤学会年会摘要。数据评估:评估了药典所述方法、2006年与14种癌症药物非标签适应症相关的文献、2006年至2008年与1种非标签适应症相关的更新文献,以及药典内容和引用的完整性。
药典所述方法与其实际做法差异很大。药典引用的现有证据很少,通常既不是最新的,也不是方法学质量最高的。药典在引用的证据、术语、细节、呈现方式和参考文献方面存在差异。对于所研究的14种非标签适应症,药典在纳入的适应症以及是否推荐和如何推荐特定药物用于特定类型癌症方面存在差异。更新时间表各不相同,文档做法使得难以确定药典内容是否以及何时更新。对于1种适应症,尽管有新发表的文章,但2006年至2008年期间药典引用并未增加。
2006年的分析仅限于14种非标签适应症;2008年的更新检查了1种适应症。仅纳入了癌症药物的非标签适应症,结果不能推广到非癌症药物或适应症。
肿瘤学家依靠药典获取非标签适应症的最新证据和报销信息。当前的药典缺乏透明度,引用的当前证据很少,并且缺乏审查或更新证据的系统方法。